9-HE, HCl Brown solid. PROTECT FROM LIGHT. HYGROSCOPIC. PACKAGED UNDER INERT GAS. A cell-permeable antitumor alkaloid that acts as a potent inhibitor of topoisomerase II (IC50 = 3.3 µM). Restores functional wild-type p53 activity via inhibition of mutant p53 protein phosphorylation. Suppresses Cdk2 activity in a concentration-dependent manner. Also reported to inhibit telomerase activity in cultured pancreatic cells, possibly through inhibition of protein kinases. Binds to the aryl hydrocarbon receptor (AhR) in rat lung cytosol and inhibits aryl hydrocarbon hydroxylase (AHH) activity in rat hepatic microsomes. Purity: ≥95% by HPLC. CAS 52238-35-4. Ref.: Mizumoto, K., et al. 2000. Cancer Lett. 149, 85. Perry, P.J., et al. 1999. Anticancer Drug Des. 14, 373. Sugikawa, E., et al. 1999. Anticancer Res. 19, 3099. Sato, N., et al. 1998. FEBS Lett. 441, 318. Ohashi, M., et al. 1995. Jpn. J. Cancer Res. 86, 819. Renault, G., et al. 1987. Toxicol. Appl. Pharmacol. 89, 281.
R: 23/24/25-40; S: 36/37/39-45 |
